Voya Investment Management LLC Purchases 69,697 Shares of Ascendis Pharma A/S $ASND

Voya Investment Management LLC grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 128.3% in the third quarter, Holdings Channel reports. The firm owned 124,029 shares of the biotechnology company’s stock after purchasing an additional 69,697 shares during the period. Voya Investment Management LLC’s holdings in Ascendis Pharma A/S were worth $28,258,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ASND. Chicago Partners Investment Group LLC raised its position in shares of Ascendis Pharma A/S by 2.3% in the third quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company’s stock worth $564,000 after buying an additional 52 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 69 shares during the period. Fifth Third Bancorp grew its position in Ascendis Pharma A/S by 48.4% during the third quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock worth $64,000 after buying an additional 91 shares in the last quarter. ProShare Advisors LLC grew its position in Ascendis Pharma A/S by 5.6% during the third quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company’s stock worth $486,000 after buying an additional 113 shares in the last quarter. Finally, AlphaCentric Advisors LLC grew its position in Ascendis Pharma A/S by 2.6% during the third quarter. AlphaCentric Advisors LLC now owns 4,706 shares of the biotechnology company’s stock worth $1,072,000 after buying an additional 121 shares in the last quarter.

Insider Transactions at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Anni Lotte Kirstine S. Pedersen sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $263.89, for a total value of $5,277,800.00. Following the completion of the sale, the executive vice president owned 19,460 shares of the company’s stock, valued at $5,135,299.40. The trade was a 50.68% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $252.73 on Friday. Ascendis Pharma A/S has a 52-week low of $188.08 and a 52-week high of $282.15. The company has a fifty day moving average of $242.58 and a 200-day moving average of $240.84. The company has a market capitalization of $15.77 billion, a P/E ratio of 16.52 and a beta of 0.40. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.29 and a current ratio of 2.89.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of research analyst reports. BMO Capital Markets restated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Cantor Fitzgerald lifted their price target on Ascendis Pharma A/S from $300.00 to $315.00 and gave the company an “overweight” rating in a research report on Friday, November 13th. Barclays boosted their price objective on Ascendis Pharma A/S from $329.00 to $341.00 and gave the stock an “overweight” rating in a report on Monday, November 16th. Jefferies Financial Group restated a “buy” rating and issued a $300.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday. Finally, Citigroup decreased their price objective on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Nineteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $312.67.

Read Our Latest Stock Analysis on ASND

Ascendis Pharma A/S Company Profile

(Free Report)

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

Further Reading

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.